InMed Pharmaceuticals (INM) Liabilities from Discontinued Operations (2025 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Liabilities from Discontinued Operations of 810334.0 for Q1 2026, up 367.22% quarter-over-quarter from 173438.0 in Q2 2025.
InMed Pharmaceuticals (INM) Liabilities from Discontinued Operations (2025 - 2026) Analysis & Trends
InMed Pharmaceuticals' Liabilities from Discontinued Operations history runs 2 years deep, the most recent figure standing at 810334.0 for Q1 2026.
- In Q1 2026, Liabilities from Discontinued Operations changed N/A year-over-year to 810334.0; the TTM figure through Mar 2026 stood at 810334.0 (changed N/A YoY), while the FY2025 annual figure was 173438.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations for Q1 2026 stood at 810334.0, up from 173438.0 in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was 810334.0 in Q1 2026, with the low at 173438.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | InMed Pharmaceuticals | 6.48 Mn | 1.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 810,334.00 |
| Mar 31, 2026 | 810,334.00 |
| Jun 30, 2025 | 173,438.00 |
| Jun 30, 2025 | 173,438.00 |